Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) ("the Inducement Award").
馬薩諸塞州波士頓，2024年11月29日（環球新聞通訊）-- cue biopharma公司（納斯達克：CUE）是一家臨床階段的生物製藥公司，開發一種新型的治療生物製品，旨在選擇性地參與並調節針對癌症和自身免疫疾病的特定t細胞。今日，公司宣佈向新任臨時首席開發官Daniel Baker萬.D授予一種誘導期權獎勵。該獎勵獲得公司大多數獨立董事的批准，作爲Dr. Baker根據納斯達克上市規則5635(c)(4)（「誘導獎勵」）進入公司工作的誘導材料。
The Inducement Award granted to Dr. Baker was an option to purchase 200,000 shares of common stock of the Company at an exercise price of $1.06 per share, representing the closing price of a share of the Company's common stock on the Nasdaq Capital Market on November 25, 2024 (the Grant Date).
授予Dr. Baker的誘導獎勵是一項選擇權，可以以每股1.06美元的行使價格購買200,000股公司的普通股，代表2024年11月25日（授予日）公司普通股在納斯達克資本市場的收盤價。
The Inducement Award will vest over two years, in four equal installments beginning six months from the Grant Date, subject to continued employment with the Company through each applicable vesting date.
該誘導獎勵將在兩年內分四次均勻解鎖，從授予日起六個月後開始，前提是在每個適用的解鎖日期之前繼續與公司保持僱傭關係。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
關於cue biopharma
Cue生物製品是一家處於臨床階段的生物製品公司，正在開發一種新型類注射生物製品，可選擇性地干預和調節病特異性t細胞，直接作用於患者體內。該公司專有的平台Immuno-STAt（t細胞的選擇性靶向和改變）以及生物製品旨在通過選擇性調節病特異性t細胞，而無需進行全面系統性免疫調節，利用體內免疫系統的治癒潛力。
總部位於馬薩諸塞州的波士頓，我們由一支經驗豐富的管理團隊和獨立的董事會領導，擁有在免疫學、免疫腫瘤學以及蛋白質生物製品的設計和臨床開發方面的深厚專業知識。
For more information please visit and follow us on X and LinkedIn.
Marie Campinell 高級總監，企業傳訊 Cue Biopharma, Inc.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫方式
Marie Campinell
高級董事，企業通信
cue biopharma，全球貨幣
mcampinell@cuebiopharma.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫
Jonathan Pappas
通信-半導體
jpappas@lifescicomms.com
譯文內容由第三人軟體翻譯。
